baseline estimated glomerular filtration rate (eGFR)

Overview

Baseline estimated glomerular filtration rate (eGFR) is the kidney function measured before treatment begins or at entry to a study, derived from serum creatinine or another filtration marker together with patient characteristics. It is used across nephrology, cardiology, oncology and pharmacology to characterize renal status, stratify risk, and decide eligibility and dose. What makes the baseline value distinct from any later one is its role as a reference: subsequent measurements are interpreted as change from it, and the slope of that change — not any single reading — is what defines progression and what nephroprotection trials are powered to detect.

It matters in drug development because the kidney clears a large share of drugs and their metabolites. A patient's baseline eGFR predicts exposure to renally eliminated agents, so it enters population pharmacokinetic models as a covariate alongside body weight, body mass index, sex, race, age, disease status and formulation, and it sets the thresholds below which a dose is reduced or the drug withheld. It has served this role in the pharmacokinetic characterization of agents such as the myeloperoxidase inhibitor mitiperstat, studied in healthy volunteers and in patients with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF).

Its use as a risk stratifier follows from the close coupling of kidney and cardiovascular disease: reduced baseline eGFR predicts mortality and cardiovascular events independently of the kidney outcomes it more obviously anticipates, which is why it appears in trial eligibility criteria across therapeutic areas rather than only in nephrology. Two cautions attach to the baseline specifically. A single pre-treatment value can misrepresent stable function if taken during acute illness or volume depletion, and an early post-treatment fall in eGFR is not necessarily injury — agents that lower intraglomerular pressure produce a dip from baseline that precedes long-term preservation of function.

Recent Publications Summary

Recent publications involving baseline glomerular filtration rate (eGFR) primarily used it as a clinical baseline characteristic in studies of cancer treatment outcomes, especially in EGFR-mutant non-small cell lung cancer (NSCLC) and other oncology settings. In a real-world single-center analysis of patients with EGFR-mutant advanced NSCLC treated with EGFR tyrosine kinase inhibitors (TKIs), baseline clinical data were used to evaluate survival outcomes by TKI generation, although the abstract does not specify eGFR-stratified results 41454492Dec. Similarly, a study examining early loss of skeletal muscle, osimertinib trough concentrations, and treatment outcomes in advanced EGFR+ NSCLC incorporated baseline patient characteristics as part of its exposure–outcome analysis, but the abstract does not report eGFR-specific findings 41997038Apr.

Baseline eGFR also appears in the context of sequential and resistance-directed EGFR-targeted therapy. A case report of EGFR exon 19 deletion lung adenocarcinoma with later airway metastases described repeated molecular profiling and sequential EGFR TKI use, including osimertinib and gefitinib, to manage acquired resistance; baseline renal function assessment would be clinically relevant in such treatment planning, but no eGFR-related outcome was reported in the abstract 41125377Oct. In pancreatic ductal adenocarcinoma, studies of vertical pathway inhibition combined KRAS, EGFR, and STAT3 targeting to achieve durable tumor regression, and another report highlighted EGFR-mediated adaptive resistance to KRASG12D blockade; however, these abstracts do not provide baseline eGFR-specific data or analyses 42224594Jun41801133Mar.

Other recent publications focused on EGFR-directed therapeutics and mechanistic oncology studies rather than renal-function stratification. These included EGFR-targeting or EGFR/HER2 dual-inhibitory compounds, EGFR-specific aptamer-modified nanoparticles for photothermal therapy, and mechanistic work on EGFR-linked signaling in glioma and NSCLC 42237319Jun41875675Mar42206690May42348047Jun41966746Apr. Across these reports, baseline eGFR was not presented as a study endpoint, and no publication in the provided set reported eGFR-specific efficacy, safety, or pharmacokinetic conclusions.

What Changes, What Holds

1. Baseline eGFR remains a prognostic covariate rather than a new treatment determinant
REINFORCES Recent oncology analyses continue to treat baseline eGFR as part of routine clinical characterization, with no reported eGFR-stratified efficacy or safety signal to revise its role. That leaves the settled view intact: baseline kidney function is still mainly a background factor that may help interpret treatment outcomes, not a newly established driver of response in EGFR-mutant NSCLC 41454492Dec41997038Apr.

2. Renal assessment stays clinically relevant in sequential EGFR-targeted therapy, but no new eGFR-specific effect is shown
REINFORCES The case-based and mechanistic reports keep baseline renal function in the realm of practical treatment planning for EGFR-directed regimens, yet they do not add evidence that baseline eGFR itself changes resistance biology or outcome. What remains unchanged is the baseline account: eGFR is a supportive clinical metric, while the new work offers no direct renal-function result to alter that understanding 41125377Oct42224594Jun.

3. EGFR-directed oncology studies still do not establish baseline eGFR as an outcome variable
REINFORCES These mechanistic and therapeutic reports broaden the EGFR literature, but they leave the kidney-function question untouched. Because the Overview already frames baseline eGFR as a clinical covariate and not a target, the absence of eGFR-specific efficacy, safety, or pharmacokinetic findings simply reinforces that it remains a contextual measure rather than a central endpoint in these studies 42237319Jun41875675Mar.